Twin-engine AI speeds COVID patients through triage

Researchers at New York University have demonstrated an AI-based way to send COVID patients from the ER to the most appropriate care setting according to their individualized risk.  

The system has two primary components. One is a deep neural network that predicts prognosis going by chest x-rays. The other is a machine learning model called gradient boosting, which in this case adds predictive power by folding in results of routine lab tests.

The team’s study has not yet been peer-reviewed but is posted for consideration on the preprint server ArXiv.

Corresponding author Krzysztof Geras, PhD, and colleagues trained their system on data from more than 3,600 patients.

The authors report that, in its trial phase, the system accurately predicted 96-hour deterioration on a test set of incoming patients.

Further, the x-ray AI performed comparably to two experienced chest radiologists in a reader study, “highlighting the potential of our data-driven approach,” they comment.

“In order to verify our system’s performance in a real clinical setting, we silently deployed a preliminary version of it at NYU Langone Health during the first wave of the pandemic, demonstrating that it can produce accurate predictions in real time,” Geras et al. write. “Overall, these results strongly suggest that our system is a viable and valuable tool to inform triage of COVID-19 patients.”

ArXiv has posted the preprint as a downloadable PDF.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.